Chris Viehbacher appointed Sanofi-Aventis CEO

Share this article:
Chris Viehbacher
Chris Viehbacher
Sanofi-Aventis announced September 10 that Chris Viehbacher will succeed Gerard Le Fur as the company's CEO, effective December 1, 2008. 

The announcement came two days after Viehbacher resigned his postion on GlaxoSmithKline's board, with plans to leave the company entirely. Viehbacher will remain executive director and president at GSK until December 1.

Viehbacher, also a PhRMA board member, was a contender for the CEO position at GSK following the retirement of Jean-Pierre Garnier last May. Andrew Witty, currently the CEO at GSK, secured that postion.

According to a statement from the Sanofi board of directors, Le Fur will stay on at Sanofi after Viehbacher becomes CEO, and will "provide his competences to the general management of the group in the scientific domain." The financial conditions of Viehbacher's hiring will be posted online in the coming days, according to the Sanofi statement. 
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.